- Home
- STG vs IMA Comparison
STG vs IMA Comparison
Compare STG & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | IMA |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | China | United States |
| Employees | N/A | 15 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.3M | 65.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | STG | IMA |
|---|---|---|
| Price | $3.21 | $4.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 4.1K | ★ 38.5K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $3.94 |
| 52 Week High | $15.00 | $17.50 |
Technical Indicators
Market Signals| Indicator | STG | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 21.89 | 24.72 |
| Support Level | N/A | $3.94 |
| Resistance Level | $4.83 | $7.28 |
| Average True Range (ATR) | 0.15 | 0.45 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 0.00 | 28.46 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.